DalsnaFinance › Analyst accuracy › KeyBanc Capital Markets › RMD target
KeyBanc raises ResMed stock price target on FY27 outlook confidence
KeyBanc raised its price target on ResMed stock (NYSE:RMD) to $267 from $255
A fact about what KeyBanc Capital Markets published, as reported by Investing.com, not a recommendation from Dalsna Finance; KeyBanc Capital Markets is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.